Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hmpv), human rhinoviruses (hrv), and infection by influenza virus type a (iav) and pharmaceutical composition comprising the anionically modified polyallylamine derivative

Abstract

The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is —SO 3 − or —H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

1 . An anionically modified polyallylamine derivative (NSPAH) with Formula 1 
       
         
           
           
               
               
           
         
         wherein each R is independently selected from such groups as —SO 3   −  and —H, and at least one R is —SO 3   −  group, 
         and n is an integer from 150 to 15000. 
       
     
     
         2 . The anionically modified polyallylamine derivative according to  claim 1 , having the form of a sodium salt. 
     
     
         3 . The anionically modified polyallylamine derivative according to  claim 1  to be used as a medicine. 
     
     
         4 . The anionically modified polyallylamine derivative according to  claim 1  to be used in therapy and prevention of infections caused by the human metapneumovirus hMPV, respiratory tract infections caused by the human rhinoviruses (HRV) and infections caused by the influenza A virus. 
     
     
         5 . A pharmaceutical composition, characterised in that it contains an anionically modified polyallylamine derivative according to  claim 1  as the active substance. 
     
     
         6 . The composition according to  claim 5  to be used as a medicine. 
     
     
         7 . The composition according to  claim 5  to be used in therapy and prevention of infections caused by the human metapneumovirus hMPV, respiratory tract infections caused by the human rhinoviruses (HRV) and infections caused by the influenza A virus. 
     
     
         8 . The composition according to  claim 5 , characterised in that it has the form of a solution or an aerosol administered to the upper respiratory tract. 
     
     
         9 . An application of the anionically modified polyallylamine derivative according to  claim 1  for production of a medicine to be used in therapy and prevention of infections caused by the human metapneumovirus hMPV, respiratory tract infections caused by the human rhinoviruses (HRV) and infections caused by the influenza A virus. 
     
     
         10 . The application according to  claim 9 , wherein the anionically modified polyallylamine derivative according to  claim 1  is used for production of a medicine having the form of a solution or an aerosol administered to the upper respiratory tract.